First personalised cancer vaccine cuts risk of disease returning in major trial
A personalised cancer vaccine given alongside an established immunotherapy drug cut the risk of melanoma returning or spreading in a large trial. Researchers say the results could be a turning point in cancer treatment, though longer-term studies are still needed.